KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Convertible Debt (2016 - 2022)

Supernus Pharmaceuticals (SUPN) has disclosed Convertible Debt for 10 consecutive years, with $400.4 million as the latest value for Q1 2022.

  • Quarterly Convertible Debt rose 9.38% to $400.4 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $400.4 million through Mar 2022, up 9.38% year-over-year, with the annual reading at $379.3 million for FY2021, 4.84% up from the prior year.
  • Convertible Debt for Q1 2022 was $400.4 million at Supernus Pharmaceuticals, up from $379.3 million in the prior quarter.
  • The five-year high for Convertible Debt was $400.4 million in Q1 2022, with the low at $318.2 million in Q1 2018.
  • Average Convertible Debt over 5 years is $350.9 million, with a median of $349.2 million recorded in 2020.
  • The sharpest move saw Convertible Debt skyrocketed 21769.57% in 2018, then increased 4.74% in 2019.
  • Over 5 years, Convertible Debt stood at $329.5 million in 2018, then grew by 4.77% to $345.2 million in 2019, then increased by 4.8% to $361.8 million in 2020, then rose by 4.84% to $379.3 million in 2021, then increased by 5.57% to $400.4 million in 2022.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $400.4 million, $379.3 million, and $374.8 million for Q1 2022, Q4 2021, and Q3 2021 respectively.